// App-Quantinova.ai

: Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Daniel J. George

Principal Investigators

  • Cora N. Sternberg

  • A. Oliver Sartor

  • Fred Saad

  • Bertrand F. TOMBAL

  • Kurt Miller

  • Jan Kalinovsky

  • XiaoLong Jiao

  • Krishna Tangirala

  • Celestia S. Higano

Medical Centers

  • Duke Cancer Institute, Durham, NC

  • Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.

  • Tulane Medical School, New Orleans, LA

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Department of Urology, Charite Berlin, Berlin, Germany

  • Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

Locations

  • United States

  • Canada

  • Belgium

  • Germany

  • Switzerland

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved